Oncology News | pharmaphorum

News

Sobi bolsters blood division via $435m ADC licensing deal

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics' lymphoma therapy Zynlonta – approved in the US last year – in Europe and other inte

Oncology

Partner Content

Bayer teams up with Huma to apply AI to lung cancer diagnosi...

Bayer teams up with Huma to apply AI to lung cancer diagnosis

News

Merck in "advanced talks" for $40bn Seagen bid; report

The rumour that Merck & Co is preparing to make a sizeable offer to buy cancer specialist Seagen won't go away.

News

FDA to decide on Roche's lymphoma drug Lunsumio before year-...

The FDA has granted a priority review to Roche's T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoT...

AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for haematological cancers.

News

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to encroach on its territory.

Sobi bolsters blood division via $435m ADC licensing deal

Bayer teams up with Huma to apply AI to lung cancer diagnosi...

Merck in "advanced talks" for $40bn Seagen bid; report

FDA to decide on Roche's lymphoma drug Lunsumio before year-...

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoT...

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Aligning with national efforts to modernise cancer diagnosti...

How to meet your physicians where they are online

News

Editor's Picks